We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells.
- Authors
Small, E J; Fratesi, P; Reese, D M; Strang, G; Laus, R; Peshwa, M V; Valone, F H
- Abstract
Provenge (Dendreon Corp, Seattle, WA) is an immunotherapy product consisting of autologous dendritic cells loaded ex vivo with a recombinant fusion protein consisting of prostatic acid phosphatase (PAP) linked to granulocyte-macrophage colony-stimulating factor. Sequential phase I and phase II trials were performed to determine the safety and efficacy of Provenge and to assess its capacity to break immune tolerance to the normal tissue antigen PAP.
- Publication
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2000, Vol 18, Issue 23, p3894
- ISSN
0732-183X
- Publication type
Journal Article
- DOI
10.1200/JCO.2000.18.23.3894